Semaglutide therapy significantly improved behavioral patterns and neurochemical markers in diabetic mice.
Diabetes and mood disorders may elevate the risk of each other due to their interconnected nature.
is associated with the development of anxiety and depression in the context of diabetes.
Semaglutide, a glucagon-like peptide-1 receptor agonist, could positively influence mood alongside its effects on type 2 diabetes.
The treatment significantly impacted behavioral assessments related to anxiety and depression in diabetic mice.
Frequency of semaglutide administration may play a crucial role in determining therapeutic outcomes.
Simplified
Diabetes and mood disorders are intricately interconnected, with each condition elevating the risk of the other. This bidirectional relationship, further exacerbated by , fosters an environment conducive to the development of anxiety and depression. Glucagon-like peptide-1 receptor agonists, such as semaglutide, offer promising therapeutic options that not only target type 2 diabetes but also can positively influence mood. Our study's primary goal was to evaluate the effectiveness of semaglutide, in mitigating anxiety and depression within an animal model of diabetes. The neuroprotective properties of semaglutide were evaluated by examining its influence on the and neurobiological markers (GFAP, NEFL, NSE, and GAL3) in the perfrontal cortex, selected for its key role in cognitive function and emotional regulation, impaired in diabetes and mood disorders. Additionally, we examined semaglutide's impact on peripheral inflammation and stress parameters to elucidate its role in modulating systemic inflammatory responses linked to mood disorders. Additionally, we conducted behavioral assessments to better understand how semaglutide influences anxiety and depression-related behaviors in diabetic mice. Semaglutide therapy significantly improved behavioral patterns and neurochemical markers in diabetic mice. The frequency of administration significantly influenced the outcomes, whereas the dosage appeared to have a limited impact. Here we show that semaglutide expands its therapeutic potential beyond diabetes, significantly influencing mood disorders through neuroinflammatory pathways. Semaglutide has the potential to be a key element in formulating integrated treatment strategies that address both metabolic health and mental well-being, ultimately enhancing the quality of life for individuals navigating these interrelated challenges.
Key numbers
9.47
Increase in GAL3 Levels
GAL3 concentration in diabetic animals compared to healthy controls.
29.5
Significance Frequency Administration
ANOVA test results indicating the impact administration frequency.
Full Text
We can’t show the full text here under this license.
Declarations. Conflict of Interest: The authors declare no competing interests. Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and was approved by the Ethics Committee for Animal Research (No. 43/2018, 26 March 2018). Informed Consent Statement: Not applicable.
